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Background: This study investigated the efficacy and safety of a new asthma therapy combining fluticasone
propionate and formoterol fumarate (fluticasone/formoterol; flutiformW), administered twice daily (b.i.d.) via a single
aerosol inhaler, compared with its individual components administered separately and placebo, in patients with
mild-to-moderate asthma.
Methods: Patients aged ≥12 years were evenly randomised to 12 weeks of treatment with fluticasone/formoterol
(100/10 μg b.i.d.), fluticasone (100 μg b.i.d.), formoterol (10 μg b.i.d.), or placebo, in this double-blind, parallel group,
multicentre study. The three co-primary endpoints were: a) change in forced expiratory volume in the first second
(FEV1) from morning pre-dose at baseline to pre-dose at week 12 for the comparison with formoterol; b) change in
FEV1 from morning pre-dose at baseline to 2 hours post-dose at week 12 for the comparison with fluticasone, and
c) time to discontinuation due to lack of efficacy from baseline to week 12 for the comparison with placebo. Safety
was assessed based on adverse events, clinical laboratory tests and vital sign evaluations.
Results: Statistically significant differences were demonstrated for all the three co-primary endpoints. Fluticasone/
formoterol combination therapy showed significantly greater improvements from baseline to end of study in the
change in pre-dose FEV1 compared with formoterol (Least Squares (LS) mean treatment difference: 0.101 L; 95%
Confidence Interval (CI): 0.002, 0.199; p = 0.045) and the change in pre-dose compared with 2 hours post-dose FEV1
versus fluticasone (LS mean treatment difference: 0.200 L; 95% CI: 0.109, 0.292; p < 0.001). The time to
discontinuation due to lack of efficacy was significantly longer for patients in the combination therapy group
compared with those receiving placebo (p = 0.015). Overall, the results from multiple secondary endpoints
assessing lung function, asthma symptoms, and rescue medication use supported the superior efficacy of the
combination product compared with fluticasone, formoterol, and placebo. The fluticasone/formoterol combination
therapy had a good safety and tolerability profile over the 12 week treatment period.
Conclusions: Fluticasone/formoterol had a good safety and tolerability profile and showed statistically superior
efficacy for the three co-primary endpoints compared to fluticasone, formoterol, and placebo, in adolescents and
adults with mild-to-moderate asthma.
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Asthma is a chronic inflammatory disorder of the air-
ways. It is associated with variable airflow obstruction
related to airway hyperresponsiveness and bronchocon-
striction. For persistent asthma, inhaled corticosteroids
(ICSs) are recommended as one of the most effective
treatments for airway inflammation. Nonetheless, for a
significant number of patients symptoms persist and
additional therapy is required [1-5].
Landmark studies in adult and adolescents have
demonstrated that patients using ICS and long-acting
β2-agonist (LABA) combination therapy achieved better
asthma control compared to more than doubling the
dose of ICS or administration of ICS in combination
with other therapeutic agents [2,4-12], while further
studies specifically in children and adolescents aged up
to 16 years have reported at least similar efficacy
with ICS/LABA compared with doubling the ICS dose
[13,14]. In addition, research has also shown that the
interactions between ICSs and LABAs potentiate each
other’s respective therapeutic effects at the molecular
level [15-18].
The ICS, fluticasone propionate (fluticasone), has a
well-established safety and efficacy profile, and exerts a
potent and sustained anti-inflammatory effect [19-22].
The LABA, formoterol fumarate (formoterol), has rapid,
dose-dependent bronchodilatory effects, with an onset of
action of 1 to 3 minutes [23], similar to salbutamol and
faster than that of salmeterol [24-27]. Extensive research
into the safety and efficacy of these two molecules is
widely documented in the literature [19-30], and sug-
gests that the fluticasone/formoterol combination may
provide clinicians with a new and efficacious treatment
for the management of persistent asthma.
The study presented here evaluated the efficacy and
safety of fluticasone and formoterol combination therapy
(fluticasone/formoterol; flutiformW), administered via a




This was a 12-week, randomised, double-blind, placebo-
and active-controlled, parallel-group study, conducted at
59 centres in North America and Europe. The study was
conducted in accordance with ICH GCP and as per the
ethical principles of the Declaration of Helsinki. The Insti-
tutional Review Boards or Independent Ethics Committees
at each participating centre reviewed and approved the
protocol (United States: Schulman Associates Institutional
Review Board Inc., Cincinnati, Ohio; University of Florida
Health Science Center IRB-01, Gainesville, Florida; Baylor
Research Institute IRB, Dallas, Texas; Marywood Univer-
sity IRB, Scranton, Pennsylvania; Canada: IRB Services,Aurora, Ontario; Research Ethics Board MUHC-MGH
Site, Montreal, Quebec; Europe: Ethics Commission of
State Pharmacological Center of Health Ministry of
Ukraine, Kiev, Ukraine). Written informed consent was
obtained from all patients (or the parents or guardians of
patients under 18 years of age) before they were enrolled
into the study.
The efficacy and safety of fluticasone/formoterol com-
bination therapy 100/10 μg, administered twice daily
(b.i.d.) (50/5 μg, 2 inhalations b.i.d.) via a single hydro-
fluoroalkane (HFA) pressurised metered-dose inhaler
(pMDI), was compared with the individual components
administered separately (fluticasone, 100 μg b.i.d. pMDI
[50 μg, 2 inhalations b.i.d.]; formoterol 10 μg b.i.d. pMDI
[5 μg, 2 inhalations b.i.d.]), and placebo (pMDI [2 inhala-
tions, b.i.d.]).
Patients
Patients of both sexes, aged 12 years and over, with a
history of asthma of at least 12 months prior to screen-
ing, as defined by the National Asthma Education and
Prevention Program [31], were considered eligible for
study enrolment. Eligible patients had either a documen-
ted history of ICS use for at least 4 weeks before screen-
ing, at a daily dose of not more than 500 μg fluticasone
HFA pMDI (or equivalent), or were not on ICS therapy
for at least 12 weeks prior to the screening visit. All
patients were required to have a Forced Expiratory Vol-
ume in the first second (FEV1) between 60% and 85%
(inclusive) of predicted normal values at both screening
and baseline visits. Patients also needed to demonstrate
FEV1 reversibility, i.e. reversible bronchoconstriction for
patients who did not have a history of documented re-
versibility within the 12 months prior to the screening
visit. These patients underwent a reversibility testing
procedure, after the pulmonary function tests at screen-
ing, defined as a ≥14.5 % increase 15–30 minutes follow-
ing albuterol/salbutamol aerosol inhalation (200 to 400
μg, as appropriate, i.e. two inhalations of 100 μg, sepa-
rated by a period of 1 minute. If reversibility was not
met, FEV1 was re-assessed within another 30 minutes,
and if still not met, two further inhalations of albuterol/
salbutamol were administered and reversibility was
re-assessed). All patients had to be able to demonstrate
satisfactory aerosol technique and accurate use of the
telephone diary system.
Patients were excluded from the study if they had a
history of life-threatening asthma within the previous 12
months or during the run-in period. Patients with a his-
tory of systemic corticosteroid use within the previous 3
months, omalizumab use within the previous 6 months,
or leukotriene antagonist use within the week before
screening, were also excluded. Other exclusion criteria
included significant, non-reversible pulmonary disease,
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screening visit or during the run-in period, significant
medical illness, a smoking history of at least 10 pack-
years or current smoking history within the previous
year, and hypersensitivity to study medication. Patients
were also excluded if they had received β-blockers, tri-
cyclic antidepressants, monoamine oxidase inhibitors,
quinidine-type antiarrhythmics, or drugs known to in-
hibit CYP3A4, within the week prior to screening. How-
ever, use of a LABA prior to screening was permitted.
Interventions
The run-in period was used to confirm that all patients
were symptomatic and to ensure that the baseline
assessments were standardised across all patients after
discontinuing their respective asthma medications. For
patients who were ICS-requiring prior to screening, the
run-in period lasted 14 ± 3 days during which time they
received fluticasone (pMDI; 50 μg b.i.d.) as maintenance
therapy. For patients with no history of ICS use, the
run-in lasted between 14 to 28 days and they received
no maintenance therapy during this time. Rescue medi-
cation was available to all patients for deteriorating
asthma symptoms. During any 7 consecutive days of the
run-in, patients were required to use at least two inhala-
tions per day of rescue albuterol/salbutamol medication
for at least 3 days and to have either 3 or more days with
asthma symptoms or one night with sleep disturbance
due to asthma. At the baseline visit, which was defined
as week 0 and followed the run-in period, patients
returned to the study site to complete the randomisation
procedures (assessment of pulmonary function and gen-
eral asthma symptom-based endpoints) and to confirm
that randomisation criteria were met.
At the end of the run-in period, eligible patients were
randomised equally into one of the following four
blinded treatment arms using minimisation with biased
coin assignment [32], stratified according to prior steroid
use, study site, and the subgroup of patients aged 12 to
18 years. Patients were provided with two inhalers: one
for fluticasone/formoterol, formoterol or placebo (which
were identical in appearance), and one for fluticasone or
a visually identical fluticasone placebo. Study medication
was administered twice daily for 12 weeks, taking two
actuations from each device twice daily (8 inhalations
per day): fluticasone/formoterol 100/10 μg (50/5 μg, 2
inhalations b.i.d.) and placebo b.i.d., fluticasone 100 μg
(50 μg, 2 inhalations b.i.d.) and placebo b.i.d., formoterol
10 μg (5 μg, 2 inhalations b.i.d.) and placebo b.i.d., or
placebo (2 inhalations, 2 devices, b.i.d.) (Figure 1). All
study medications were administered via a pMDI with-
out the use of a spacer. Patients were required to have a
1-minute interval between inhalations, always use the
pMDIs in the same sequence and rinse their mouththoroughly after dosing. All other asthma medications
were prohibited during the study, except for albuterol/
salbutamol, the use of which was permitted, as needed,
in case of worsening asthma symptoms. An Interactive
Voice Response System was used for patient enrolment,
treatment allocation, and generation of patient identifi-
cation number. The use of dummy placebo inhalers
ensured that blinding was maintained throughout the
study. The investigators, study site personnel, and repre-
sentatives involved in monitoring, data management,
any other aspect of the study, including sponsor
personnel, were blinded throughout the study. Treat-
ment assignment was strictly confidential and accessible
only to authorised persons until the time of unblinding.
Patient adherence to assigned study medication regi-
men was assessed based on the data recorded via a tele-
phone diary system. Each patient recorded the number
of actuations of study and rescue medication they had
used during both the run-in and the treatment periods.
A safety follow-up was carried out two weeks after last
dose of study medication by telephone.
Efficacy assessments
The efficacy of fluticasone/formoterol combination ther-
apy in comparison with fluticasone, formoterol, and pla-
cebo was evaluated using three co-primary endpoints:
the mean change in FEV1 (as measured in the clinic)
from pre-dose at baseline to pre-dose at week 12 (a
comparison of fluticasone/formoterol versus formoterol
alone) was used to assess the contribution of the antiin-
flammatory component from the fluticasone/formoterol
combination; the mean change in FEV1 (in clinic) from
pre-dose at baseline to 2 hours post-dose at week 12 (a
comparison of fluticasone/formoterol versus fluticasone
alone) was used to assess the contribution of the bron-
chodilator component from the combination product,
and discontinuation due to lack of efficacy was used to
evaluate the efficacy of the fluticasone/formoterol com-
bination compared with placebo. Lack of efficacy was
defined by asthma exacerbations and loss of asthma con-
trol (see below for definitions), and these two classifica-
tions were combined for the analysis. In order to
demonstrate superior efficacy, fluticasone/formoterol
therapy had to achieve statistical significance over the
relevant comparator treatments for each of the three co-
primary endpoints.
Secondary efficacy endpoints comprised additional pul-
monary function tests including FEV1 % predicted normal,
Forced Vital Capacity (FVC), frequency of asthma exacer-
bations, and data gathered from patients’ telephone diaries
including morning and evening Peak Expiratory Flow Rate
(PEFR), asthma symptom scores, sleep disturbance scores,
and frequency of rescue medication use.
Screening
Patients with a 
history of ICS use
prior to screening
Patients with no 
history of ICS use
prior to screening
14±3 days 
(50 µg fluticasone pMDI b.i.d.)
Fluticasone/formoterol 100/10 µg b.i.d.
Fluticasone 100 µg b.i.d.
Formoterol 10 µg b.i.d.
Placebo b.i.d.
Stratification by steroid use prior to screening
12 weeks
14–28 days
Run-In Period* Treatment Period*
Figure 1 Study design. *Albuterol/salbutamol pro re nata (as needed) as rescue medication. b.i.d. = twice daily; ICS = inhaled corticosteroid;
pMDI = pressurised metered dose inhaler.
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weeks 2, 4, 8, and 12 by spirometry in accordance with
the American Thoracic Society/European Respiratory
Society Task Force guidelines [33]. Predicted FEV1
values were determined using the values of Polgar and
Promadhat [34] for patients aged 12–17 years, and those
of Crapo et al. [35] for patients aged 18 years and older.
Spirometry values were also adjusted for race. PEFR was
measured twice daily, pre-dose, by means of a Micro-
Peak peak flow meter (Micromedical, Chatham
Maritime, Kent, UK), and patients recorded the results
using the telephone diary system.
The frequency and severity (defined as either ‘mild-to-
moderate’ or ‘severe’) of asthma exacerbations were
recorded throughout the study. Mild-to-moderate
exacerbations were defined as any of the following
occurring for at least 2 consecutive days: i) pre-dose
PEFR measurements more than 30% below the values
measured at baseline, or ii) awakening during the night
because of asthma, or iii) the use of additional rescue
medication of more than three inhalations per day com-
pared with baseline. Severe exacerbations were defined
as the deterioration in asthma that required additional
therapy (for example, systemic steroids), or an emer-
gency visit or hospitalisation due to asthma.
Asthma symptoms, scored on a six-point scale ranging
from 0 to 5 (0 = no symptoms; 5 = asthma so severe that
the patient was unable to go to work or school or to
carry out normal daily activities), and sleep distur-
bances, scored on a five-point scale ranging from 0 to
4 (0 = slept through the night, no asthma; 4 = could
not sleep at all because of asthma), were recorded via
the telephone diary system.
Patients were withdrawn from the study because of
lack of treatment efficacy (asthma exacerbations and loss
of asthma control) if any of the following five criteria
were met: i) a severe asthma exacerbation requiring
emergency treatment, hospitalisation, or use of any
asthma medication not permitted in the study protocol,
ii) a decrease in pre-dose FEV1 (as measured in the
clinic) of more than 20% from baseline, iii) a decrease in
morning pre-dose PEFR (from telephone diaries) ofmore than 25% from baseline on more than 3 of the 7
days before a study visit, iv) excessive use (more than 12
actuations per day) of rescue medication on more than 3
of the 7 days before a study visit, or v) nocturnal awa-
kening due to asthma, that required rescue medication,
on more than 2 of 7 days before a study visit.Safety assessments
Safety assessments were carried out throughout the study
based on adverse events reported, vital signs, a 12-lead
electrocardiogram (ECG), and clinical laboratory testing.Statistical analyses and sample size calculation
Efficacy analyses were performed on the full analysis set
(FAS) (all patients who received at least one dose of
study medication, had a baseline FEV1 measurement and
at least one post-baseline pre-dose and 2-hour post-dose
FEV1 measurement), the per-protocol (PP) population
(all patients in the FAS who did not have a major proto-
col violation, which included patients who did not take
study medication on at least 50% of the days that the pa-
tient was in the study or if the patient did not return for
two study visits in a row), and the safety population (all
randomised patients who received at least one inhalation
of study medication).
The change in morning pre-dose FEV1 from baseline
to pre-dose at weeks 2, 4, 8, and 12, and change in
morning pre-dose FEV1 from baseline to 2-hours post-
dose at weeks 2, 4, 8, and 12 were compared between
the treatment groups using analysis of covariance
(ANCOVA), with treatment group, centre, and previous
steroid use as main effects, and baseline FEV1 as a con-
tinuous covariate. Missing data were replaced using the
last observation carried forward (LOCF) approach. To
analyse the time to discontinuation due to lack of effi-
cacy, a stratified log-rank test was performed adjusting
for treatment group and previous steroid use. In this su-
periority analysis (which used a two-sided t-test), super-
iority for each the three co-primary endpoints was
confirmed if the lower limit of the 95% confidence inter-
val (CI) for the between-treatment difference did not
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for the CI to be above a pre-defined threshold.
For the secondary endpoints, the differences between
groups for the change from baseline in PEFR, asthma
symptom scores, sleep disturbance scores, and rescue
medication use were analysed using the ANCOVA
model described above, with the relevant baseline value
as the continuous covariate. Differences in the frequency
of exacerbations between groups were tested by logistic
regression analysis with effects for treatment group and
previous steroid use, and differences between groups for
the percentage of days with an asthma exacerbation and
percentage of asthma control days were assessed using
van Elteren’s method for combining Wilcoxon rank sum
test results from independent strata, with prior steroid
use as the stratum for the analysis.
Provided all three co-primary endpoints were statisti-
cally significant, the secondary endpoints were then eval-
uated using a sequential gatekeeper approach [36] for
the three treatment comparisons, according to the fol-
lowing order: i) fluticasone/formoterol combination
therapy versus placebo, and ii) fluticasone/formoterol
combination therapy versus fluticasone alone and fluti-
casone/formoterol combination therapy versus formo-
terol alone.
The first four secondary endpoints were analysed
firstly for combination therapy vs. placebo, in the follow-
ing order, based on the mean change from baseline to
week 12: morning PEFR, evening PEFR, use of rescue
medication, and asthma symptom scores. Provided that
each of these analyses returned statistically significant
results for combination product vs. placebo (p < 0.05),
the subsequent analyses (combination therapy vs. flutica-
sone alone and vs. formoterol alone) could then be
carried out in the same order. Statistical analyses were
two-sided and significance was measured at the 0.05α
level. If both tests were significant at the 0.05α level, the
next endpoint could be evaluated for confirmatory statis-
tical significance. If one of the two tests was not significant
at the 0.05α level, for example the analysis of morning
PEFR for combination therapy vs. fluticasone alone, the
other test (morning PEFR for combination product vs.
formoterol alone) could be evaluated for statistical sig-
nificance at the 0.025α level, however all formal testing
of the remaining secondary endpoints was suspended
(i.e. for both combination product vs. fluticasone and
vs. formoterol). If the analyses were not statistically sig-
nificant for the combination product versus either com-
parator then, once again, all remaining confirmatory
sequential testing was formally suspended. If the sequen-
tial gatekeeper approach for the three comparative tests
was statistically significant for each of the four end-
points, confirmatory sequential testing of the remaining
secondary endpoints was carried out in the followingorder, using the same Hochberg methodology as
described above: percentage of symptom-free days
(defined as days with an asthma symptom score of zero),
percentage of rescue medication-free days (days with no
use of rescue medication), percentage of asthma control
days (days with asthma symptom score of zero, sleep
disturbance score of zero, and no use of rescue medica-
tion), the proportion of patients with treatment-
emergent asthma exacerbations, sleep disturbance scores,
and the percentage of awakening-free nights (nights with
a sleep disturbance score of zero). Pre-specified sub-
group analyses were performed for all three co-primary
endpoints based on prior ICS use, using an ANCOVA,
with age and study site as factors, and using the LOCF
approach on the FAS.
Safety analyses were performed for all randomised
patients who received at least one inhalation of study
medication (the safety population).
For pre-dose or 2-hours post-dose FEV1 measures, a
sample size of 92 patients per treatment group in the
study would have 85% power to detect a significant dif-
ference between two treatment groups using a two-sided
t-test with α=0.05, assuming a difference of 0.2 L with
respect to mean change from morning pre-dose baseline
to either morning pre-dose FEV1 at week 12 or 2-hour
post-dose FEV1 at week 12, and a common standard de-
viation (SD) of 0.45. It was therefore planned to enrol
108 patients in each group to account for an approxi-
mately 15% drop out rate. Assuming that 10% of flutica-
sone/formoterol and 30% of placebo group patients
would discontinue due to lack of efficacy, with 92
patients per treatment group there would be 90% power
to detect this difference using a two-sided log-rank test
with α = 0.05.
Results
A total of 475 patients were randomised to treatment,
including 33 adolescents (6.9%). Of the 475 patients, 333
took part at sites based in the United States, 80 were
based in Canada, and 62 in the Ukraine, and, overall,
367 (77.3%) patients completed the study (Figure 2).
Treatment groups were well-matched with regard to
demographics and baseline characteristics, with little dif-
ference between groups with respect to lung function re-
versibility. Prior to screening, a total of 29.4% of patients
had received ICS monotherapy, and 20.0% had received
combined ICS and LABA combination therapy (Table 1).
The median FEV1 % predicted value at baseline ranged
from 72.0 to 75.0 (Table 1). Mean compliance rates ran-
ged from 84% to 85% across treatment arms. There were
459 randomised patients in the FAS (115, 117, 116, and
111 in the combination, fluticasone, formoterol, and pla-
cebo groups, respectively); 408 in the PP population










n = 19 (16.1%)
Adverse Event
n = 1 (0.8%)
Consent
Withdrawn
n = 4 (3.4%)
Lost to follow-up
n = 2 (1.7%)
Lack of efficacy
n = 7 (5.9%)
Other





n = 97 (81.5%)
Discontinued
n = 22 (18.5%)
Adverse Event
n = 1 (0.8%)
Consent
Withdrawn
n = 5 (4.2%)
Lost to follow-up
n = 3 (2.5%)
Lack of efficacy
n = 9 (7.6%)
Other





n = 90 (75.0%)
Discontinued
n = 30 (25%)
Adverse Event
n = 1 (0.8%)
Consent
Withdrawn
n = 4 (3.3%)
Lost to follow-up
n = 2 (1.7%)
Lack of efficacy
n = 13 (10.8%)
Other




n = 81 (68.6%)
Discontinued
n = 37 (31.4%)
Adverse Event
n = 3 (2.5%)
Consent
Withdrawn
n = 4 (3.4%)
Lost to follow-up
n = 2 (1.7%)
Lack of efficacy
n = 22 (18.6%)
Other




n = 367 (77.3%)
Discontinued
n = 108 (22.7%)
Adverse Event
n = 6 (1.3%)
Consent
Withdrawn
n = 17 (3.6%)
Lost to follow-up
n = 9 (1.9%)
Lack of efficacy
n = 51 (10.7%)
Other
n = 25 (5.3%)
Figure 2 Patient flow diagram.
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all 475 patients were in the safety population.
Primary efficacy endpoints
The three co-primary endpoints demonstrated superior
efficacy of fluticasone/formoterol combination therapy
compared to fluticasone, formoterol, and placebo,
respectively (Table 2).
The fluticasone/formoterol combination showed clin-
ically relevant improvements in FEV1 from pre-dose at
baseline to pre-dose and 2-hour post-dose at week 12
(Table 2). Furthermore, the contribution of the flutica-
sone component in the combination product, as ana-
lysed by the mean change in FEV1 from pre-dose at
baseline to pre-dose at week 12, demonstrated statisti-
cally significant improvements for patients in the com-
bination therapy treatment arm compared with those
administered formoterol alone (LS mean difference = 0.101
L; 95% CI: 0.002, 0.199; p = 0.045). Similarly, the
contribution of the formoterol component of the
combination product, as analysed by the mean change in
FEV1 from pre-dose at baseline to 2 hours post-dose at
week 12, demonstrated statistically significant improve-
ments for patients in the combination therapy treatment
arm compared with those administered fluticasone alone(LS mean difference = 0.200 L; 95% CI: 0.109, 0.292;
p < 0.001) (Table 2). The improvements in pre-dose FEV1
(Figure 3A) and 2-hour post-dose FEV1 (Figure 3B) with
fluticasone/formoterol were demonstrated throughout the
entire treatment period as shown by pulmonary function
tests carried out at Weeks 2, 4, 8, and 12. Secondary ana-
lyses also showed that fluticasone/formoterol provided sig-
nificantly greater improvements than fluticasone alone in
FEV1 from pre-dose at baseline to pre-dose at week 12, and
numerically greater improvements in FEV1 from pre-dose
at baseline to 2 hours post-dose at week 12 compared with
formoterol alone (Table 2).
Fluticasone/formoterol combination therapy was also
shown to be superior to placebo with respect to the time
to discontinuation due to lack of efficacy (due to either
asthma exacerbation or to loss of asthma control) (log-
rank p = 0.015) (Table 2). Furthermore, fewer patients
discontinued due to lack of efficacy in the combination
therapy group (6.1%) compared with those in the flutica-
sone group (7.7%), formoterol group (11.2%) or the pla-
cebo group (16.2%) (Table 2).
Secondary efficacy endpoints
The secondary efficacy endpoints evaluated lung func-
tion, disease control and asthma symptoms. Overall, all

















Female 72 (62.6) 71 (60.7) 63 (54.3) 70 (63.1) 276 (60.1)
Male 43 (37.4) 46 (39.3) 53 (45.7) 41 (36.9) 183 (39.9)
Ethnic origin, n (%)
White/Caucasian 89 (77.4) 88 (75.2) 83 (71.6) 79 (71.2) 339 (73.9)
Black 13 (11.3) 16 (13.7) 21 (18.1) 22 (19.8) 72 (15.7)
Asian 6 (5.2) 4 (3.4) 5 (4.3) 4 (3.6) 19 (4.1)
Hispanic 6 (5.2) 8 (6.8) 6 (5.2) 5 (4.5) 25 (5.4)
Other 1 (0.9) 1 (0.9) 1 (0.9) 1 (0.9) 4 (0.9)
Age, years
Mean (SD) 39.8 (14.54) 38.3 (14.45) 39.1 (15.26) 38.1 (13.67) 38.8 (14.47)
Age categories, n (%)
12 to 17 years 7 (6.1) 9 (7.7) 9 (7.8) 6 (5.4) 31 (6.8)
≥ 18 years 108 (93.9) 108 (92.3) 107 (92.2) 105 (94.6) 428 (93.2)
Steroid use, n (%)
Freea 59 (51.3) 60 (51.3) 58 (50.0) 55 (49.5) 232 (50.5)
Requiringb 56 (48.7) 57 (48.7) 58 (50.0) 56 (50.5) 227 (49.5)
Prior ICS and ICS/LABA use, n (%)
ICS only 31 (27.0) 39 (33.3) 30 (25.9) 35 (31.5) 135 (29.4)
ICS and LABA 25 (21.7) 18 (15.4) 28 (24.1) 21 (18.9) 92 (20.0)
Duration of asthma, yearsc
Mean (SD) 18.9 (13.40) 20.6 (13.84) 20.3 (14.48) 21.4 (12.83) 20.3 (13.64)
FEV1 % predicted
d at baselinee
Mean (SD) 73.2 (7.54) 73.5 (8.14) 73.2 (7.79) 72.0 (7.97) 73.0 (7.86)
Median 72.0 75.0 73.0 72.0 73.0
FEV1 at baseline
e, L
Mean (SD) 2.416 (0.5790) 2.425 (0.6625) 2.459 (0.6231) 2.352 (0.6114) 2.414 (0.6192)
Median 2.370 2.330 2.375 2.250 2.340
Reversibility at screening, %
n = 114 n = 117 n = 116 n = 111 n = 458
Mean (SD) 23.2 (10.1) 22.8 (9.0) 21.8 (8.4) 22.8 (8.3) 22.6 (9.0)
Median 19.3 19.5 18.7 20.0 19.2
N = total number of patients; n = number of patients in specified category; SD = standard deviation; b.i.d. = twice daily; ICS = inhaled corticosteroids; LABA = long
acting beta agonist; FEV1 = Forced Expiratory Volume in the first second.
a. Patient with no history of steroid use for at least 12 weeks prior to the screening visit.
b. Patient who used an inhaled steroid regimen at a dose not greater than 500 μg/day fluticasone (or equivalent steroid) for at least 4 weeks prior to screening.
c. Duration of asthma calculated as (Date of screening visit from Demographics CRF - Asthma diagnosis date)/ 365.25 and rounded to 1 decimal place.
d. Based on standardised predicted FEV1 values.
e. Baseline was the last available value prior to dosing at the baseline/week 0 visit.
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http://www.biomedcentral.com/1471-2466/12/67of these evaluations supported the superior efficacy of
fluticasone/formoterol combination therapy compared
with the individual components and placebo. The com-
bination product demonstrated numerically greater
improvements for a number of the secondary endpoint
evaluations versus all three of the comparators, with
many endpoints meeting the criteria for statistical sig-
nificance as per the sequential gatekeeping approach.The mean increase in morning and evening PEFR
values from baseline to week 12 was statistically signifi-
cantly greater (p < 0.01) for patients on the combination
product compared with those administered fluticasone,
formoterol or placebo (Figure 4).
Disease control, as evaluated by asthma control days,
rescue medication-free days, symptom-free days, and
awakening-free nights (Table 3), demonstrated numerically
Table 2 Mean change in FEV1 (L) from pre-dose at baseline to pre-dose and 2-hour post-dose at week 12, (LOCF), time















Mean (SD) 2.416 (0.5790) 2.425 (0.6625) 2.459 (0.6231) 2.352 (0.6114)
Change in FEV1 from pre-dose at baseline to pre-dose at week 12
LS Mean (SE) 0.195 (0.038) 0.092 (0.037) 0.094 (0.038) 0.047 (0.037)
Difference from fluticasone/formoterol 100/10 μg b.i.d.: contribution from fluticasone component
LS Mean (SE) 0.103 (0.050) 0.101 (0.050) 0.147 (0.051)
95% CI 0.005, 0.201 0.002, 0.199 0.048, 0.247
p-value 0.040 0.045 0.004
Change in FEV1 from pre-dose at baseline to 2 hours post-dose at week 12
LS Mean (SE) 0.392 (0.035) 0.191 (0.034) 0.330 (0.035) 0.124 (0.035)
Difference from fluticasone/formoterol 100/10 μg b.i.d.: contribution from formoterol component
LS Mean (SE) 0.200 (0.047) 0.062 (0.047) 0.267 (0.047)
95% CI 0.109, 0.292 −0.030, 0.153 0.175, 0.360
p-value < 0.001 0.187 < 0.001
Discontinuation due to lack of efficacy
Number, % 7 (6.1) 9 (7.7) 13 (11.2) 18 (16.2)
Time to discontinuation, weeksa
Mean 6.9 4.7 4.6 5.5
p-value b 0.015
b.i.d. = twice daily; N = total number of patients; SD = standard deviation; LS = least squares; SE = standard error; NA = not applicable; CI = confidence interval;
LOCF = last observation carried forward; FEV1 = Forced Expiratory Volume in the first second.
a. Time to discontinuation due to lack of efficacy calculated as (Date of early discontinuation - Date of first study drug administration+1)/7 and rounded to 1
decimal place (based on all patients who discontinued).
b. p-value based on stratified log-rank test adjusting for prior steroid use for fluticasone/formoterol 100/10 μg b.i.d. versus placebo.
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http://www.biomedcentral.com/1471-2466/12/67greater improvements for fluticasone/formoterol compared
to all the comparator treatments. However, significant in-
ferential statistical testing was only exploratory based on
the sequential gatekeeping approach. Patients adminis-
tered fluticasone/formoterol 100/10 μg b.i.d. demon-
strated a five-fold increase in the percent of asthma
control days from baseline (12.8%) to week 12 (69.1%),
corresponding to 0.9 days per week at the start of the
study compared to 4.8 days by the end of treatment. The
mean increase in percent of asthma control days was
56.3% for the combination product, 44.0% for the flutica-
sone, 41.9% for the formoterol, and 36.0% for the placebo
groups.
Overall, a lower percentage of patients on combination
therapy experienced any asthma exacerbation (20.0%)
compared to those administered the monotherapies (23.9%
on fluticasone; 28.4% on formoterol) or placebo (32.4%),
although the differences did not reach statistical signifi-
cance. For patients in the fluticasone/formoterol group,
2.6% experienced a severe exacerbation, compared to 3.4%
on fluticasone, 6.9% on formoterol, and 9.0% of patients on
placebo (p = 0.048 for placebo vs fluticasone/formoterol).Similarly, a larger mean increase in rescue medication-
free days was observed in the combination therapy arm
than in any of the comparator groups. In the flutica-
sone/formoterol group, a greater than three-fold in-
crease was seen in the number of rescue medication-free
days from baseline (21.8%) to week 12 (77.7%), corre-
sponding to an improvement from 1.5 days/week to 5.4
days/week. Overall, the mean increase in percent rescue
medication-free days was 55.9% in the combination ther-
apy group compared to 43.3%, 41.9%, and 39.4% for the
fluticasone, formoterol, and placebo groups, respectively
(Table 3).
The mean percentage of symptom-free days at week
12 (77.4%, corresponding to 5.4 days/week) in the com-
bination therapy group was 2.5-fold than seen at base-
line (28.0%, corresponding to 2.0 days/week). The mean
increase in symptom-free days in this group was 49.4%,
compared with 37.3%, 38.0% and 35.6% in the flutica-
sone, formoterol and placebo groups, respectively.
This trend was also seen in the number of awakening-
free nights for patients in the fluticasone/formoterol
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Figure 3 A – Mean change in FEV1 (L): mean change from baseline to pre-dose at weeks 2, 4, 8, and 12, Full Analysis Set (LOCF). * P-
value ≤ 0.05 versus fluticasone/formoterol 100/10 μg b.i.d. combination therapy treatment group. Baseline means were 2.416 L, 2.425 L, 2.459 L,
and 2.352 L for the fluticasone/formoterol, fluticasone, formoterol, and placebo treatment groups, respectively, for all patients in the Full Analysis
Set. b.i.d. = twice daily; FEV1 = forced expiratory volume in the first second; LOCF = last observation carried forward. Figure 3B – Mean change
in FEV1 (L): mean change from baseline to 2 hours post-dose at weeks 2, 4, 8, and 12, Full Analysis Set (LOCF). * P-value ≤ 0.05 versus
fluticasone/formoterol 100/10 μg b.i.d. combination therapy treatment group. Baseline means were 2.416 L, 2.425 L, 2.459 L, and 2.352 L for the
fluticasone/formoterol, fluticasone, formoterol, and placebo treatment groups, respectively, for all patients in the Full Analysis Set. b.i.d. = twice
daily; FEV1 = forced expiratory volume in the first second; LOCF = last observation carried forward.
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http://www.biomedcentral.com/1471-2466/12/67was approximately 1.5-fold greater by week 12 (87.9%)
compared to baseline (59.1%), which corresponds to 4.1
awakening-free nights at baseline and 6.2 awakening-
free nights at the end of study. The mean increase
was 28.8% for patients in the combination therapy
group compared to 25.4%, 19.6%, and 20.9% for
patients in the fluticasone, formoterol, and placebo
groups, respectively.
Asthma symptoms, as evaluated by rescue medication
use, asthma symptom scores, and sleep disturbance
scores, recorded daily by the patients, demonstrated nu-
merically greater improvement for those administered
fluticasone/formoterol compared to the individual com-
ponents and placebo. Rescue medication use was statisti-
cally significant for the combination versus all three
comparator groups, as evaluated using the sequential
gatekeeping approach (Table 4).Sub-group analyses
Pre-specified subgroup analyses were performed based
on ICS use prior to study entry, although it should be
acknowledged that this study was not powered to assess
these endpoints statistically. For patients with no history
of ICS use prior to study enrolment, the difference be-
tween the mean change in pre-dose FEV1 from baseline
to week 12 between the combination therapy and formo-
terol groups was not statistically significant (LS mean
treatment difference: 0.094 L; 95% CI: -0.050, 0.237;
p = 0.200). However, the mean increase in FEV1 from
pre-dose at baseline to 2 hours post-dose at week 12 was
statistically significant in the combination therapy group
compared with fluticasone alone (LS mean treatment differ-
ence: 0.212 L; 95% CI: 0.070, 0.354; p = 0.004).
For patients with a prior history of ICS use, the com-














Formoterol 10 µg b.i.d. (n = 116)
Placebo (n = 111)
Fluticasone/formoterol 100/10 µg b.i.d. (n = 115)









































Figure 4 Morning and evening PEFR (L/min): mean change from baseline to week 12, Full Analysis Set. * P-value < 0.01 versus
fluticasone/formoterol 100/10 μg b.i.d. combination therapy treatment group. † P-value < 0.001 versus fluticasone/formoterol 100/10 μg b.i.d.
combination therapy treatment group. b.i.d. = twice daily; PEFR = peak expiratory flow rate; SE = standard error. Changes from baseline are
shown as least-squares mean ± SE for the full analysis set.
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http://www.biomedcentral.com/1471-2466/12/67to each of the comparators for the mean change from
pre-dose FEV1 at baseline to both pre-dose at week
12 (LS mean treatment difference combination prod-
uct compared with formoterol alone: 0.139 L; 95% CI:
0.000, 0.277; p = 0.050) and 2 hours post-dose at
week 12 (LS mean treatment difference combination
product vs. fluticasone alone: 0.172 L; 95% CI: 0.054,
0.291; p = 0.005).
With respect to discontinuations due to lack of treat-
ment efficacy, no statistically significant treatment group
difference was identified among patients with no history
of prior steroid use (log-rank p = 0.795); 4 patients
(7.3%) from the combination therapy group and 3 (5.8%)
from the placebo group discontinued prematurely. For
patients with a history of ICS use, fluticasone/formoterol
combination was demonstrated to be statistically signifi-
cantly superior to placebo (p = 0.002, log-rank test); 3
patients (5.7%) receiving fluticasone/formoterol discon-
tinued early compared to 15 patients (36.6%) adminis-
tered placebo.
Safety and tolerability
Combination therapy with fluticasone/formoterol was well
tolerated. Adverse events were reported by 38 (32.2%)
patients in the fluticasone/formoterol group, 47 (39.5%)
patients in the fluticasone group, 44 (36.7%) patients in
the formoterol group, and 46 patients (39.0%) in the
placebo group (Table 5). No deaths or asthma exacerba-
tions requiring hospitalisation were reported. Most ad-
verse events were mild or moderate in severity. Only
one serious adverse event occurred during the study, a
case of right-sided renal colic in a 70-year-old malepatient receiving fluticasone/formoterol therapy which
was not considered by the Investigator to be treatment-
related.
The most common adverse event leading to premature
discontinuation of treatment in any group was asthma
(fluticasone/formoterol combination therapy group,
2.5%; fluticasone group, 3.4%; formoterol group, 6.7%,
placebo group, 11.9%). The most frequently reported ad-
verse events occurring in more than 2% of patients in
any treatment group are summarised in Table 5. There
were no incidences of oropharyngeal candidiasis or dys-
phonia in any of the treatment groups. In addition, there
were no clinically relevant changes or group differences
for laboratory values (including glucose and potassium),
vital signs, or ECG parameters.
Discussion
The study presented here evaluated the efficacy and
safety of fluticasone/formoterol 100/10 μg b.i.d. combin-
ation therapy compared to the individual components
administered separately and placebo over a 12-week
treatment period. The patients who took part in the
study were adolescents and adults with mild-to-
moderate asthma who were either already on ICS medi-
cation (either with or without a LABA) or who were
ICS-free prior to screening.
The three co-primary endpoints all demonstrated that
the fluticasone/formoterol combination product was su-
perior in efficacy compared to each of the comparators.
The first two co-primary efficacy endpoints evaluated
lung function, based on FEV1 measurements, and com-
pared the combination product with fluticasone alone
Table 3 Asthma control days (%), rescue medication-free days (%), symptom-free days (%), and awakening-free nights














Asthma control days (%) n = 109 n = 114 n = 112 n = 105
Baselinea, mean (SD) 12.8 (20.14) 14.3 (22.62) 11.5 (19.21) 10.0 (18.11)
Week 12, mean (SD) 69.1 (37.69) 58.3 (42.02) 53.4 (40.11) 46.0 (41.22)
Change to week 12
Mean (SD) 56.3 (39.11) 44.0 (39.49) 41.9 (42.13) 36.0 (39.27)
Difference from fluticasone/formoterol 100/10 μg b.i.d.b
p-value* 0.017† 0.117 0.012†
Rescue medication-free days (%) n = 112 n = 116 n = 115 n = 109
Baselinea, mean (SD) 21.8 (24.38) 21.4 (25.55) 19.5 (24.51) 17.2 (20.14)
Week 12, mean (SD) 77.7 (32.12) 64.8 (39.49) 61.4 (37.19) 56.6 (39.95)
Change to week 12
Mean (SD) 55.9 (36.43) 43.3 (37.69) 41.9 (39.49) 39.4 (38.69)
Difference from fluticasone/formoterol 100/10 μg b.i.d.b
p-value* 0.020† 0.125 0.012†
Symptom-free days (%) n=110 n=114 n=115 n=108
Baselinea, mean (SD) 28.0 (26.72) 28.6 (29.97) 22.6 (27.01) 22.7 (27.75)
Week 12, mean (SD) 77.4 (35.21) 65.9 (38.59) 60.5 (38.67) 58.3 (38.99)
Change to week 12
Mean (SD) 49.4 (38.17) 37.3 (39.79) 38.0 (42.64) 35.6 (42.18)
Difference from fluticasone/formoterol 100/10 μg b.i.d.b
p-value* 0.027† 0.195 0.151
Awakening-free nights (%) n = 112 n = 116 n = 115 n = 108
Baselinea, mean (SD) 59.1 (33.79) 62.1 (33.73) 62.9 (34.51) 56.3 (37.40)
Week 12, mean (SD) 87.9 (26.73) 87.5 (26.77) 82.6 (31.57) 77.2 (34.17)
Change to week 12
Mean (SD) 28.8 (33.91) 25.4 (35.92) 19.6 (35.68) 20.9 (41.05)
Difference from fluticasone/formoterol 100/10 μg b.i.d.b
p-value* 0.790 0.055 0.052
b.i.d. = twice daily; N = total number of patients; n = number of patients in treatment group; FAS = full analysis set; SD = standard deviation.
a. Baseline was the 7-day average calculated on the last 7 days prior to the first dose of study drug.
b. Analysis method was Cochran-Mantel-Haenszel using van Elteren’s method for combining Wilcoxon rank sum test results from independent strata, with
previous steroid use and site as the strata for the analysis.
*All p values were exploratory.
† p ≤ 0.050 versus fluticasone/formoterol 100/10 μg b.i.d. combination therapy but not statistically significant as per the sequential gatekeeping approach.
Nathan et al. BMC Pulmonary Medicine 2012, 12:67 Page 11 of 15
http://www.biomedcentral.com/1471-2466/12/67and with formoterol alone, respectively. The improve-
ments in FEV1 from pre-dose at baseline to pre-dose
and 2 hours post-dose at week 12 were clinically relevant
for patients receiving fluticasone/formoterol. Moreover,
improvements seen in the combination therapy group
were numerically and statistically significantly greater for
the combination product compared with the monother-
apies administered alone. Tachyphylaxis has been
reported with formoterol monotherapy [37] and should
be considered when interpreting the results. Nonethe-
less, fluticasone/formoterol combination therapy pro-
vided improvements from baseline in lung function over12 weeks of treatment in this study. This improvement
was seen throughout the study period, as shown by pul-
monary function tests at weeks 2, 4, 8, and 12, and were
supported by the secondary efficacy endpoints evaluating
lung function, for example the morning and evening
PEFR measurements.
The third co-primary endpoint, evaluated for the flu-
ticasone/formoterol versus placebo treatment arms,
showed that the combination product was statistically
significantly superior to placebo with respect to the
time to discontinuation due to lack of efficacy. Fewer
patients in the combination therapy group prematurely
Table 4 Use of rescue medication (number of inhalations/day), asthma symptom scores, and sleep disturbance scores:














Rescue medication use (inhalations/day) n = 112 n = 116 n = 115 n = 109
Baselinea, mean (SD) 2.8 (2.05) 3.0 (2.24) 3.0 (2.07) 3.0 (1.68)
Change to week 12
Mean (SE)b −2.22 (0.165) −1.64 (0.160) −1.62 (0.163) −1.16 (0.162)
Difference from fluticasone/formoterol 100/10 μg b.i.d.b
LS Mean (SE) −0.58 (0.217) −0.60 (0.218) −1.06 (0.222)
95% CI −1.01, -0.15 −1.03, -0.17 −1.50, -0.63
p-value* 0.008** 0.006** <0.001**
Asthma symptom scores n = 110 n = 114 n = 115 n = 108
Baselinea, mean (SD) 1.0 (0.60) 1.0 (0.64) 1.1 (0.61) 1.1 (0.62)
Change to week 12
LS Mean (SE)b −0.72 (0.060) −0.59 (0.058) −0.54 (0.059) −0.51 (0.059)
Difference from fluticasone/formoterol 100/10 μg b.i.d.b
LS Mean (SE) −0.13 (0.079) −0.18 (0.079) −0.21 (0.081)
95% CI −0.29, 0.03 −0.33, -0.02 −0.37, -0.05
p-value* 0.100 0.027† 0.011**
Sleep disturbance scores n = 112 n = 116 n = 115 n = 108
Baselinea, mean (SD) 0.5 (0.54) 0.5 (0.45) 0.4 (0.49) 0.6 (0.57)
Change to week 12
LS Mean (SE)b −0.36 (0.033) −0.34 (0.032) −0.28 (0.033) −0.27 (0.033)
Difference from fluticasone/formoterol 100/10 μg b.i.d.b
LS Mean (SE) −0.02 (0.043) −0.09 (0.044) −0.10 (0.044)
95% CI −0.11, 0.07 −0.17, 0.00 −0.18, -0.01
p-value* 0.632 0.053 0.031†
b.i.d. = twice daily; N = number of patients in treatment group; n = number of patients with data available; CI = confidence interval; FAS = full analysis set; LS =
least squares; SD = standard deviation; SE = standard error.
a. Baseline was the 7-day average calculated in the last 7 days prior to the first dose of study drug.
b. LS mean, SE, CI and p-value are from ANCOVA with factors for treatment group, site, and prior steroid use, with baseline value as a continuous covariate.
* All p-values were exploratory.
** p ≤ 0.050 versus fluticasone/formoterol 100/10 μg b.i.d. combination therapy and statistically significant as per the sequential gatekeeping approach.
† p ≤ 0.050 versus fluticasone/formoterol 100/10 μg b.i.d. combination therapy but not statistically significant as per the sequential gatekeeping approach.
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http://www.biomedcentral.com/1471-2466/12/67left the study because of lack of treatment efficacy
compared to those in any of the other three treatment
groups.
Probably the most important and clinically relevant
endpoint for patients is disease control. This was evalu-
ated in this study by analysing the number of asthma
control days, asthma exacerbations, rescue medication-
free days, symptom-free days, and awakening-free nights.
Although not a validated endpoint, the definition of
asthma control used in this study was robust and highly
relevant (recorded as days with no asthma symptoms,
no sleep disturbance due to asthma, and no use of res-
cue medication). The use of the gatekeeping approach
meant that these secondary endpoints could not be sub-
jected to confirmatory statistical testing. However, the
greatest improvements in these symptomatic endpointswere seen for patients administered the combination
product compared to those receiving either of the indi-
vidual treatments or placebo. Patients treated with the
combination product also reported fewer asthma exacer-
bations throughout the study compared to each of the
other treatment arms.
A potential criticism of this study could be the recruit-
ment of patients who were not on ICS monotherapy at
baseline, perhaps suggesting the potential for over-
treatment of patients with milder asthma. This would not
be consistent with GINA guidelines, which suggest a step-
wise treatment approach whereby patients with persistent
asthma should be initiated on a low to medium dose of
inhaled corticosteroids prior to treatment escalation in the
event of a suboptimal response. Nonetheless, the median
FEV1 as a percentage of predicted value at baseline was














Any AE, n (%) 38 (32.2) 47 (39.5) 44 (36.7) 46 (39.0)
Any serious AE, n (%) 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
Any severe AE, n (%) 6 (5.1) 6 (5.0) 11 (9.2) 16 (13.6)
Any AE leading to study discontinuationa, n (%) 4 (3.4) 5 (4.2) 9 (7.5) 17 (14.4)
Any AE with probably or possible relationship to study drug, n (%) 5 (4.2) 9 (7.6) 10 (8.3) 12 (10.2)
Any AE leading to death, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Treatment-emergent AEs reported for >2% of patients in any treatment group, n (%)
Infections and infestations 20 (16.9) 27 (22.7) 14 (11.7) 15 (12.7)
Upper respiratory tract infection 7 (5.9) 6 (5.0) 3 (2.5) 4 (3.4)
Nasopharyngitis 3 (2.5) 9 (7.6) 3 (2.5) 3 (2.5)
Urinary tract infection 3 (2.5) 3 (2.5) 1 (0.8) 1 (0.8)
Respiratory, thoracic and mediastinal disorders 8 (6.8) 8 (6.7) 14 (11.7) 17 (14.4)
Asthmab 3 (2.5) 4 (3.4) 9 (7.5) 14 (11.9)
Cough 4 (3.4) 2 (1.7) 1 (0.8) 1 (0.8)
Nervous system disorders 5 (4.2) 10 (8.4) 6 (5.0) 11 (9.3)
Headache 2 (1.7) 6 (5.0) 3 (2.5) 9 (7.6)
Gastrointestinal disorders 3 (2.5) 5 (4.2) 3 (2.5) 5 (4.2)
Diarrhoea 2 (1.7) 0 (0.0) 1 (0.8) 3 (2.5)
AEs = adverse events; N = total number of patients; n = number of patients in specified category; b.i.d. = twice daily.
Adverse events were coded using MedDRA™ version 9.0. At each level of summation (preferred term, system organ class and overall), each patient was counted
only once. Percentages were based on the number of patients in the population for each treatment group.
a. Six of the 35 patients (1 fluticasone/formoterol, 1 fluticasone, 1 formoterol, and 3 placebo) had treatment-emergent adverse events reported as the primary
reason for early discontinuation from the study. The remaining 29 patients (3 fluticasone/formoterol, 4 fluticasone, 8 formoterol, and 14 placebo) had lack of
efficacy reported as the primary reason for early discontinuation from the study. A serious adverse event was one which resulted in death, was life threatening,
resulted in persistent or significant disability/incapacity, inpatient hospitalisation or prolongation of existing hospitalisation, congenital anomaly or birth defect, or
an important medical event.
b. An exacerbation of asthma was considered as an adverse event if it did not resolve with the study drug, including rescue albuterol/salbutamol, and additional
medication was required (e.g., systemic glucocorticosteroids).
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http://www.biomedcentral.com/1471-2466/12/67relatively low (72–75% across the treatment groups), sug-
gesting that a notable proportion of patients had moder-
ately severe asthma and significant pulmonary impairment.
Furthermore, whilst the authors would not advocate a
change to established treatment paradigm, two observa-
tions are nonetheless evident from this study. Firstly,
pre-specified subgroup analysis of the populations of
patients with no history of ICS use at baseline and those
who were on an ICS at baseline demonstrate that both
subgroups showed improvements for the two co-
primary lung function endpoints over 12 weeks of treat-
ment. Secondly, the treatment benefits for ICS-requiring
patients were similar to or better than those for ICS-naïve
patients on all three co-primary endpoints (versus the
relevant comparator). These data may reflect the clinical
benefit that patients could receive when stepping-up treat-
ment to combination therapy.
Fluticasone/formoterol combination therapy demon-
strated a good safety profile and was well-tolerated dur-
ing the 12-week treatment period. There were no deaths
or asthma exacerbations requiring hospitalisation in thisstudy, and the adverse event profile of the combination
therapy was similar to that of its individual components
administered separately and placebo.
This study provides strong evidence of the benefits of a
new combination of fluticasone/formoterol, administered
via a single aerosol inhaler, in adolescent and adult
patients with mild-to-moderate asthma.Conclusions
The data presented here are consistent with those
observed in previous studies exploring the benefits of
this ICS/LABA combination therapy [27,28]. The co-
administration of formoterol and fluticasone shows
superiority to the individual components administered
separately and placebo for all three co-primary end-
points and confers significant benefits in terms of lung
function, disease control, and asthma symptoms. This
study therefore demonstrates that fluticasone/formoterol
combination therapy is an efficacious and well tolerated
treatment for asthma.
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